

## Panacea Biotec

[View the current Panacea Biotec Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/27843-Panacea+Biotec.html>)

### Contact Details:

**B-1 Extn. A-27, Mohan Co-op. Industrial Estate,  
Mathura Road  
New Delhi  
New Delhi  
110044  
India**

Tel: 91 11 26945270,26974500,41678000,41679000

Fax: 91 11 41044550

Email: [corporate@panaceabiotec.com](mailto:corporate@panaceabiotec.com)

The role of a health management company is highly crucial in a developing country like India having a huge population of over 1000 million. On one hand morbidity and mortality is much higher; on the other hand per capita expenditure is far less than many developed countries of the world. Global companies have been dominating the Indian pharmaceutical and health industry since its independence in 1947. However, in the last two decades, Indian pharmaceutical companies have made a significant progress in providing much needed healthcare solutions to the people of India. Their significant role is being recognized in international markets as well.

Though product quality is quintessential, especially in health products- affordability by the masses is also a crucial factor that would support the cause of a healthy living. Panacea Biotec has emerged as a leading health management company of India addressing both areas of concern.

Panacea Biotec is India's frontline research based health management company involved in research, manufacturing and marketing of pharmaceuticals, biopharmaceuticals, new chemical entities, natural products and vaccines .

The product portfolio includes highly innovative prescription products in important therapeutic areas like pain management, diabetes & cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal care products and vaccines.

Rooted in Quality, Innovation & Continuous learning, Panacea Biotec has crossed significant milestones in a decade of growth .

Panacea Biotec consistent efforts and performance has been well acknowledged in the industry and accordingly it has been ranked amongst the top 3 biotechnology companies in India .

**Recent Publications by Panacea Biotec:**



- [Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys.](#)  
*This report describes the immunogenicity and protective efficacy of...*15th August, 2009  
Panacea Biotec Ltd., New Delhi, India.- Biotechnol J. 2009 Mar;4(3):391-9. ([DOI Direct Link](#))
- [Critical evaluation of permeation enhancers for oral mucosal drug delivery.](#)  
*Background: Drug delivery via oral mucosa is an alternative method of...*12th August, 2009  
Panacea Biotec Ltd., GRAND Centre, Mahape, Navi Mumbai, Maharashtra,- Drug Dev Ind Pharm. 2009 Aug 7. ([DOI Direct Link](#))
- [Oral strip technology: overview and future potential.](#)  
*Over the recent past, many of the research groups are focusing their...*30th June, 2009  
Drug Delivery Division, Panacea Biotec Ltd., Samarpan complex, Chakala,- J Control Release. 2009 Oct 15;139(2):94-107. Epub 2009 Jun 24. ([DOI Direct Link](#))
- [Fluidization technologies: Aerodynamic principles and process engineering.](#)  
*The concept of fluidization has been adapted to different unit processes...*3rd April, 2009  
Drug Delivery Division, Panacea Biotec Ltd., Samarpan Complex, Chakala,- J Pharm Sci. 2009 Nov;98(11):3933-60. ([DOI Direct Link](#))
- [A simple and rapid method for quantifying 2-phenoxyethanol \(2-PE\) in Diphtheria, Tetanus and w-Pertussis \(DTwP\) vaccine.](#)  
*The authors developed a simple and rapid method for quantitation of...*29th March, 2008  
Panacea Biotec Ltd., Lalru, Patiala 140501, Punjab, India.- Biologicals. 2008 Jan;36(1):61-3. Epub 2007 Aug 28. ([DOI Direct Link](#))
- [A multicenter, prospective, open-label, non-comparative study to evaluate the immunogenicity and tolerance of a new, fully liquid pentavalent vaccine \(DTwP-HepB-Hib vaccine\).](#)  
*The current study was planned to assess the immunogenicity and...*6th December, 2007  
Clinical Research Dept., Panacea Biotec Ltd., New Delhi, India.- Hum Vaccin. 2007 Jul-Aug;3(4):116-20. Epub 2007 Feb 24.
- [Tacrolimus \(Pan Graf\) in live related renal transplantation: an initial experience of 101 recipients in India.](#)  
*BACKGROUND: Success of modern transplantation is in large part due to the...*20th July, 2007  
Department of Surgery and Nephrology and Pathology, All India Institute of- Transplant Proc. 2007 Apr;39(3):747-9. ([DOI Direct Link](#))
- [Nitrooxyethylation reverses the healing-suppressant effect of Ibuprofen.](#)  
*Nonsteroidal antiinflammatory drugs like ibuprofen impede tissue repair by...*17th April, 2007  
Panacea Biotec Ltd, Mohan Cooperative Industrial Estate, New Delhi, India.- Mediators Inflamm. 2006;2006(4):24396. ([DOI Direct Link](#))
- [Evaluation of efficacy and safety of fixed dose lovastatin and niacin\(ER\) combination in asian Indian dyslipidemic patients: a multicentric study.](#)  
*Asian Indian dyslipidemia is characterized by: borderline high low-density...*22nd March, 2007  
Clinical Research Division, Panacea-Biotec Ltd, New Delhi, India.- Vasc Health Risk Manag. 2006;2(1):87-93.
- [Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats.](#)  
*The nitric oxide/guanylyl cyclase, cyclic guanosine...*29th December, 2006  
Pharmacology R&D, Panacea Biotec Ltd., Lalru 140501, Punjab, India.- Pharmacol Rep. 2006 May-Jun;58(3):373-80.
- [Monovalent polio immunisation--a strategy for India.](#)  
*For the global eradication of poliomyelitis to succeed it is necessary to...*9th August, 2006  
Panacea Biotec Ltd, New Delhi 110044.- J Indian Med Assoc. 2005 Dec;103(12):682-5.
- [Sildenafil induces hyperalgesia via activation of the NO-cGMP pathway in the rat neuropathic pain model.](#)  
*Persistent stimulation of nociceptors and C-fibers by tissue injury causes...*5th August, 2006  
Pharmacology R and D, Panacea Biotec Ltd, Lalru, 140501 Punjab, India.- Inflammopharmacology. 2006 Mar;14(1-2):22-7. ([DOI Direct Link](#))

- [Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats.](#)  
*Inflammatory bowel disease (IBD) is a relapsing inflammation of intestine...*30th April, 2004  
Research and Development Division, Panacea Biotech Ltd., P.O. Lalru 140- Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):163-75.
- [Paradoxical effects of opioid antagonist naloxone on SSRI-induced analgesia and tolerance in mice.](#)  
*Selective serotonin reuptake inhibitors (SSRIs) have been used clinically...*19th February, 2004  
Research and Development Division, Panacea Biotech Ltd., Punjab, India.- Pharmacology. 2003 Nov;69(3):115-22. ([DOI Direct Link](#))
- [Suitability of limited sampling strategy to cyclosporine A oral formulation.](#)  
*Therapeutic drug monitoring of cyclosporine A in renal transplant patients...*5th March, 2003  
Department of Medical Research, Panacea Biotech Ltd., B-1 Ext./A-27, Mohan- Indian J Exp Biol. 2000 Aug;38(8):824-6.

#### Press Releases on Panacea Biotech:

<a href="#">Reportlinker Adds World Bioplastics Industry</a>	10th November, 2009	Reportlinker	NEW YORK, Nov. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. World Bioplastics Industry <a href="http://www.reportlinker.com/p0158674/World">http://www.reportlinker.com/p0158674/World</a>
<a href="#">Heart Disease and Cellular Therapy: Start of Phase III Clinical Trial "PERFECT" Using Autologous CD133+ Bone Marrow Stem Cells</a>	29th October, 2009	Miltenyi Biotec GmbH	BERGISCH GLADBACH, Germany, October 29 /PRNewswire/ -- Miltenyi Biotec announces the treatment of the first patient in a phase III clinical trial termed PERFECT. The trial aims at determining
<a href="#">New Report Just Published: World Prostate Cancer Therapeutics Market Report</a>	7th July, 2009	Reportlinker	NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Prostate Cancer Therapeutics Market <a href="http://www.reportlinker.com/p0119471/World">http://www.reportlinker.com/p0119471/World</a>
<a href="#">AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis</a>	1st June, 2009		LONDON, June 1 /PRNewswire/ -- Privately owned UK biotech company Daval International Limited ( <a href="http://www.davalinternational.com">http://www.davalinternational.com</a> ) has been informed by Australia's Therapeutic Goods Administration
<a href="#">Myelin Removal Beads: Premium Efficiency for Neural Cell Separations and Antibody Stainings</a>	20th May, 2009	Miltenyi Biotec GmbH	BERGISCH GLADBACH, Germany, May 20 /PRNewswire/ -- Miltenyi Biotec announces the worldwide and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and

- [K'taka among 10 states in national immunization programme against pneumonia](#)  
*PharmaBiz: Nov 6 2009 5:53AM Matching: panacea biotec*
- [Panacea Biotech net sales at Rs 166 cr in Q2](#)  
*PharmaBiz: Nov 6 2009 7:03AM Matching: panacea biotec*
- [Panacea's Q2FY10 net turnover touches \\$35.25 mn](#)  
*Bio Spectrum Asia: Oct 30 2009 11:10AM Matching: panacea biotec*
- [The conservative path to biotech protection](#)  
*Managing IP: Oct 12 2009 2:04PM Matching: panacea biotec*
- [Indian vaccine for swine flu to be ready by March](#)  
*The Hindu: Sep 15 2009 10:06PM Matching: panacea biotec*
- [North Indian pharma: Focusing on R&D and tie-ups to meet challenging conditions](#)  
*PharmaBiz: Aug 24 2009 2:58AM Matching: panacea biotec*
- [Panacea Biotech bags USD 222 mn UNICEF order for pentavalent vaccine](#)  
*PharmaBiz: Aug 19 2009 12:59PM Matching: panacea biotec*

#### Panacea Biotech Patents:



- 7371412- [Pharmaceutical compositions comprising an extract of Euphorbia prostrata](#)
- 5716609- [Therapeutic anti-inflammatory and analgesic composition containing nimesulide for use transdermally and a process for the manufacture thereof](#)
- 5876751- [Antispasmodic and anti-inflammatory composition and a process for the manufacture thereof](#)
- 5945398- [Pharmaceutical compositions containing cyclosporin](#)
- 6008191- [Pharmaceutical compositions containing cyclosporin](#)
- 6017932- [Pharmaceutical compositions containing at least one NSAID having increased bioavailability](#)
- 6160019- [Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs](#)
- 6258816- [Anti-allergy anti-inflammatory composition](#)
- 6306838- [Targeted vesicular constructs for cyto protection and treatment of h. pylori](#)
- 6346511- [Pharmaceutical composition comprising cyclosporin](#)
- 6451302- [Parenteral water-miscible non-intensely colored injectable composition of non-steroidal anti-inflammatory drugs](#)
- 7122198- [Fast dissolving composition with prolonged sweet taste](#)
- 7195769- [Pharmaceutical compositions of anti-tubercular drugs and process for their preparation](#)
- 5688829- [Therapeutic injectable analgesic composition containing nimesulide and a process for the manufacture thereof](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

